Advertisement
Advertisement
APGE
Apogee Therapeutics, Inc. Common Stock
86.50
USDSponsored
+3.38
+4.07%
Apr 09, 15:59 UTC -4
Closed
After-Market
85.17
-1.34
-1.55%
APGE Earnings Reports
Positive Surprise Ratio
APGE beat 5 of 11 last estimates.
45%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$1.12
Implied change from Q4 25 (Revenue/ EPS)
--
/+8.74%
Implied change from Q1 25 (Revenue/ EPS)
--
/+17.89%
Apogee Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 02, 2026, APGE reported earnings of -1.03 USD per share (EPS) for Q4 25, beating the estimate of -1.07 USD, resulting in a 4.31% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.31% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of -1.12 USD, with revenue projected to reach -- USD, implying an increase of 8.74% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Forte Biosciences, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.23
Actual
-$1.39
Surprise
-12.31%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
OS Therapies Incorporated
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.50
Surprise
-260.49%
VolitionRX Limited Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.05
Surprise
-22.35%
Cyclerion Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.21
Surprise
+45.82%
Femasys Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.80%
Tevogen Bio Holdings Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$2.04
Actual
-$1.45
Surprise
+28.92%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
FAQ
What were Apogee Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Apogee Therapeutics, Inc. Common Stock reported EPS of -$1.03, beating estimates by 4.31%, and revenue of $0.00, 0% as expectations.
How did the market react to Apogee Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 1.31%, changed from $70.00 before the earnings release to $70.92 the day after.
When is Apogee Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Apogee Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Apogee Therapeutics, Inc. Common Stock is expected to report EPS of -$1.12 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement